



# SOMETHING BETTER THAN HOPE

## **Amendments to DISC, TRAN and CLIN Concept Proposals**

**Gil Sambrano**

Vice President  
Portfolio Development and Review

December 11, 2020

**CIRM**  
CALIFORNIA / STEM CELL AGENCY



# Background

- CIRM has historically offered recurring discovery (DISC), translational (TRAN) and clinical (CLIN) funding opportunities to support stem cell-based research. In the last two years, limits on available budget have prevented opening some of our core programs and/or modifying them to address urgent needs such as COVID-19.
- CIRM is proposing changes to the DISC, TRAN and CLIN concepts to effectively relaunch these core programs starting January 2021 under Proposition 14.



# Background

- The proposed initial relaunch of the core programs would restore features such as award limits, award duration and other elements to that available before the COVID-19 program was implemented.
- The proposed concepts would retain recent elements such as addressing the needs of underserved communities and add new requirements such as a requirement for a data sharing plan.
- The changes also align the concepts with Prop 14 requirements and definitions.



# Global Changes to DISC, TRAN and CLIN Concepts

- Addition of requirement for applicants to provide a Data Sharing Plan and allowance to include related costs in budget.
- Removal of requirement to deem gene therapy projects a “vital research opportunity” by the GWG.
- Broadly included gene therapy projects as in-scope for CIRM funding.
- Addition of requirement to address needs of underserved racial/ethnic communities, if not previously included.



# Proposed Changes to DISC2 Program

Discovery awards to identify a candidate therapeutic, medical device, diagnostic, or tool

- Award limit restored to direct project costs of up to \$900,000 for therapeutic candidates and \$500,000 for a diagnostic, device or tool.
- Maximum award duration restored to 24 months
- PI percent effort requirement restored to 20%
- Project initiation updated to within 60 days of approval



# Proposed Changes to TRAN Program

## (TRAN1, TRAN2, TRAN3, TRAN4)

Translational awards to advance a candidate therapeutic, medical device, diagnostic, or tool to the clinic or commercialization.

- Project initiation updated to within 60 days of approval



# Proposed Changes to CLIN Program

## (CLIN1, CLIN2, CLIN3)

Awards to support IND-enabling activities and clinical trials

- Award limit restored for clinical trials in CLIN2
- Award duration restored to a maximum of 4 years for CLIN2
- Project initiation restored to within 45 days of approval for CLIN2
- Changed percent effort requirement for project manager to 50% for CLIN2
- Clarified that minimally manipulated bone marrow, cord blood or unmodified HSC are eligible candidates for phase 2 or phase 3 clinical trials



# Requested Action

CIRM requests the Board approve the proposed amendments to the DISC, TRAN, and CLIN concept plans.